- Sunshine Heart (SSH +17%) pops on a report out of Runway Research saying the company's C-Pulse Heart Assist System is a "game changing device" that could lead to a buyout worth as much as $50 per share.
- SSH received unconditional FDA approval for the C-Pulse(R) system's U.S. pivotal trial in November, 2012.
- With the device, Runway says that SSH is targeting the New York Heart Association's Class III and ambulatory Class IV Congestive Heart Failure market, which is an enormous untapped opportunity with approximately 1.5M patients in the U.S. and another 3.7M patients in Europe.
- If the company penetrates just 10% of this market, the firm says the opportunity could reach over $5B.
Sunshine Heart jumps on an upbeat report from Runway Research
Aug 5 2013, 12:09 ET